4-Benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: Optimization and in vitro evaluation against clinically important HIV mutant strains

Journal of Medicinal Chemistry

Volumn 47, Issue 22, 2004, Pages 5501-5514

  Benjahad, Abdellah ^a   Courté, Karine ^a   Guillemont, Jérôme ^b   Mabire, Dominique ^b   Coupa, Sophie ^b   Poncelet, Alain ^b   Csoka, Imre ^b   Andries, Koen ^c   Pauwels, Rudi ^d   De Béthune, Marie Pierre ^d   Monneret, Claude ^a   Bisagni, Emile ^a   Nguyen, Chi Hung ^a   Grierson, David S ^a  

^a CNRS   (France)

^b Medicinal Chemistry Department   (France)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d Virco BVBA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 [5 ETHYL 6 METHYL 3 (DIMETHYLAMINO) 2 OXO 1,2 DIHYDROPYRIDIN 4 YLCARBONYL]PHENYL]ACRYLONITRILE; 4 BENZOYL 3 DIMETHYLAMINOPYRIDIN 2 (1H) ONE DERIVATIVE; 4 BENZYL 3 DIMETHYLAMINOPYRIDIN 2 (1H) ONE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EFAVIRENZ; EMIVIRINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION; VIRUS MUTANT;

AMINOPYRIDINES; ANTI-HIV AGENTS; BENZENE DERIVATIVES; BENZOATES; CELL LINE; HIV-1; HUMANS; MUTAGENESIS, SITE-DIRECTED; MUTATION; NEVIRAPINE; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; URACIL;

EID: 6044252411     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0407658     Document Type: Article

References (57)

1. Mocroft, A.; Ledergerber, B.; Katlama, C.; Kirk, K.; Reiss, P.; d'Arminio Monforte, A.; Knysz, B.; Dietrich, M.; Phillips, A. N.; Lundgren, J. D. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003, 362, 22-29.
2. Richman, D. D. HIV chemotherapy. Nature 2001, 410, 995-1001.
3. Vella, S.; Palmisano, L. Antiretroviral therapy: state of the HAART. Antiviral Res. 2000, 45, 1-7.
4. De Clercq, E. Novel compounds in preclinical/early clinical development for the treatment of HIV infections. Rev. Med. Virol. 2000, 10, 255-277.
5. Lucas, G. M.; Chaisson, R. E.; Moore, R. D. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologie failure and adverse drug reactions. Ann. Intern. Med. 1999, 13, 81-87.
6. Yerly, S.; Kaiser, L.; Race, E.; Bru, J. P.; Clavel, F.; Perrin, L. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 1999, 354, 729-733.
7. Carr, A.; Samaras, C. K.; Thorisdottir, A.; Kaufmann, G. R.; Ghisholm D. J.; Cooper, D. A. Diagnosis, prediction, and natural course of HIV-1 protease inhibitor associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353, 2093-2099.
8. Carr, A.; Cooper, D. A. Adverse effects of antiviral therapy Lancet 2000, 356, 1423-1430.
9. Bastard, J.-P.; Caron, M.; Vidal, H.; Jan, V.; Auclair, M.; Vigouroux, C.; Luboinski, J.; Laville, M.; Maachi, M.; Girard, P.-M.; Rozenbaum, W.; Levan, P.; Capeau, J. Association between altered expression of adipogenic factor SREBP1 in lipotrophic adipose tissue from HIV-1 infected patients and abnormal adipocyte differentiation and insulin resistance Lancet 2002, 359, 1026-1031.
10. De Clercq, E. New developments in anti-HIV chemotherapy. Biochim. Biophys. Acta 2002, 1587, 258-275.
11. Ren, J.; Esnouf, R.; Garman, E.; Somers, D.; Ross, C.; Kirby, I.; Keeling, J.; Darby, G.; Jones, Y.; Stuart, D.; Stammers, D. High-resolution structures of HIV-1 RT from four RT-inhibitor complexes Nat. Struct. Biol. 1995, 2, 293-302.
12. Esnouf, R.; Ren, J.; Ross, C.; Jones, Y.; Stammers, D.; Stuart, D. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnudeoside inhibitors. Nat. Struct. Biol. 1995, 2, 303-308.
13. Smerdon, S. J.; Jager, J.; Wang, J.; Kohlstaedt, L. A.; Chirino, A. J.; Priedman, J. M.; Rice, P. A.; Steitz, T. A. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 3911-3915.
14. Jonckheere, H.; Anne, J.; De Clercq, E. The HlV-1 reverse transcription (RT) process as target for RT inhibitors. Med. Res. Rev. 2000, 20, 129-154.
15. Jain, R. G.; Furfine, E. S.; Pednrault, L.; White, A. J.; Lenhard, J. M. Metabolic complications associated with antiretroviral therapy. Antiviral Res. 2001, 51, 151-177.
16. Hajos, G.; Riedi, S.; Molnar, J.; Szabo, D. Nonnucleoside reverse transcriptase inhibitors. Drugs Future 2000, 25, 47-62.
17. Tantillo, C.; Ding, J.; Jacobo-Molina, A.; Nanni, R. G.; Boyer, P. L.; Hughes, S. H.; Pauwels, R.; Andries, K.; Janssen, P. A.; Arnold, E. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J. Mol. Biol. 1994, 243, 369-387.
18. Larder, B. A. Interactions between drug resistance mutations in human immunodeficieincy virus type 1 reverse transcriptase. J. Gen. Virol. 1994, 75, 951-957.
19. Kleim, J. P.; Winkler, I.; Rosner, M. A.; Kirsch, R.; Rubsamen-Waigmann, H.; Paessens, A.; Riess, G. In Vitro Selection For Different Mutational Patterns in the HIV-1 Reverse Transcriptase Using High and Low Selective Pressure of the Non-Nucleoside Reverse transcriptase Inhibitor HBY 097. Virology 1997, 231, 112-118.
20. Bacheler, L. T. Resistance to Non-Nucleoside Inhibitors of HIV-1. Drug Resist. Updates 1999, 2, 56-67.
21. Deeks, S. G. Nonnucleoside reverse Transcriptase inhibitor resistance. J. Acquired Immune Defic. Syndr. 2001, 26, S25-S33.
22. Hoffmann, C.; Kamps, B. S. HIV medicine 2003 (www.HIV.com); Flying Publisher: Paris, France, 2003.
23. De Clercq, E. Perspectives of nonnucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Il Farmaco 1999, 54, 26-45.
24. Ruiz, N.; Nusrat R.; Lauenroth-Mai E.; Berger, D.; Walworth, C.; Bacheler, L. T.; Ploughman, L.; Tsang, P.; Labriola, D.; Echols, R.; Levy, R. Study DPC 083-203, a phase II comparison of 100 and 200 mg once-daily DPC 083 and 2 NRTIs in patients failing a NNRTI-containing regimen. Presented at the 9th Conference on Retroviruses and Opportunistic Infection, Feb 24-28, 2002, Seattle, WA, Abstract 6.
25. Ludovici, D. W.; De Corte, B. L.; Kukla, M. J.; Ye, H.; Ho, C. Y.; Lichtenstein, M. A.; Kavash, R. W.; Andries, K; de Be'thune, M.-P.; Azijn, H.; Pauwels, R.; Lewi, P. J.; Heeres, J.; Koymans, L. M. H.; de Jonge, M. R.; Van Aken, K. J. A.; Daeyaert, F. F. D.; Das, K.; Arnold, E.; Janssen, P. A. J. Evolution of Anti-HIV Drug Candidates. Part 3: Diarylpyrimidine (DAPY) Analogues. Bioorg. Med. Chem. Lett. 2001, 11, 2235-2239.
26. Ren, J.; Nichols, C.; Bird, L. E.; Fujiwara, T.; Sugimoto, H.; Stuart, D. I.; Stammers, D. K. Binding of the Second Generation Nonnucleoside Inhibitor S-1153 to HIV-1 Reverse Transcriptase Involves Extensive Main Chain Hydrogen Bonding. J. Biol. Chem. 2000, 275, 14316-14320.
27. Freeman, G.; Romines, K; Schaller, L.; Ferris, R.; Roberts, G.; Short, S.; Weaver, K; Hazen, R.; Creech, K.; St Clair, M.; Tidwell, J.; Cowan, J.; Chamberlain, P.; Rena, J.; Stuart, D.; Stammers, D.; Andrews, C.; Koszalka, G.; Burnette, T.; Chan, J.; Boone, L. Identification of Novel Benzophenone HIV Non-nucleoside Reverse Transcriptase Inhibitors with Unique Drug Resistance Properties. Presented at the 2nd International Aids Society Conference on HIV Pathogenesis and Treatement 2003, Paris, France, Abstract 538.
28. (a) Dolle, V.; Fan, E.; Nguyen, C. H.; Aubertin, A.-M.; Kirn, A.; Andreola, M. L.; Jamieson, G.; Tarrago-Litvak, L.; Bisagni, E. A New Series of Pyridinone Derivatives as Potent Non-Nucleoside Human Immunodeficiency Virus Type 1 Specific Reverse Transcriptase Inhibitors. J. Med. Chem. 1995, 38, 4679-4686.
29. (b) Bisagni, E.; Dolle, V.; Nguyen, C.-H.; Legraverend, M.; Aubertin, A.-M.; Kirn, A.; Andreola, M. L.; Tarrago-Litvak, L. 4-Aryl-thio-pyridin-2(1H)- ones, medecines containing them and their uses in the treatment of illnesses linked to HIV-1 and 2. WO9705113, 1997.
30. (a) Dolle, V.; Nguyen, C. H.; Legraverend, M.; Aubertin, A.-M.; Kirn, A.; Andreola, M. L.; Ventura, M.; Tarrago-Litvak, L.; Bisagni, E. Synthesis and Antiviral Activity of 4-Benzyl Pyridinone Derivatives as Potent and Selective Non-Nucleoside Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitors. J. Med. Chem. 2000, 43, 3949-3962.
31. (b) Bisagni, E.; Dolle, V.; Nguyen, C.-H.; Monneret, C.; Grierson, D. S.; Aubertin. A. M. 3-(Amino- or aminoalkyl)pyridinone derivatives and their use for the treatment of HIV related diseases. WO9955676, 1999.
32. Tanaka, H.; Baba, M.; Ubasawa, M.; Takashima, H.; Sekiya, K.; Nitta, I.; Shigeta, S.; Walker, R. T.; De Clercq, E.; Miyasaka, T. Synthesis and anti-HIV activity of 2-, 3-, and 4-substituted analogues of 1-[(2-hydroxyethoxy)methyl]- 6-(phenylthio)thymine (HEPT). J. Med. Chem. 1991, 34, 1394-1399.
33. Tanaka, H.; Baba, M.; Hayakawa, H.; Sakamaki, T.; Miyasaka, T.; Ubasawa, M.; Takashima, H.; Sekiya, K.; Nitta, I.; Shigeta, S.; Walker, R. T.; Balzarini, J.; De Clercq, E. A new class of HTV-1 specific 6-substituted acyclouridine derivatives: synthesis and anti-HIV-1 activity of 5- or 6-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). J. Med. Chem. 1991, 34, 349-357.
34. Tanaka, H.; Takashima, H.; Ubasawa, M.; Sekiya, K; Nitta, I.; Baba, M.; Shigeta, S.; Walker, R. T.; De Clercq, E.; Miyasaka T. Synthesis and antiviral activity of deoxy analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents. J. Med. Chem. 1992, 35, 4713-4719.
35. Tanaka, H.; Takashima, H.; Ubasawa, M.; Sekiya, K; Nitta, I.; Baba, M.; Shigeta, S.; Walker, R. T.; De Clercq, E.; Miyasaka, T. Structure-activity relationships of 1-[(2-hydroxyethoxy)-methyl]-6-(phenylthio)thymine analogues: effect of substitutions at the C-6 phenyl ring and at the C-5 position on anti-HIV-1 activity. J. Med. Chem. 1992, 35, 337-345.
36. Tanaka, H.; Takashima, H.; Ubasawa, M.; Sekiya, K.; Inouye, N.; Baba, M.; Shigeta, S.; Walker, R. T.; De Clercq, E.; Miyasaka, T. 1-[(2-Hydroxyethoxy) methyl]-5-(phenylthio)thymine (HEPT) as Potent and Selective Anti-HIV-1 Agents. J. Med. Chem. 1995, 38, 2860-2865.
37. Goldman, M. E.; O'Brien, J. A.; Ruffing, T. L.; Schleif, W. A.; Sardana, V. V.; Byrnes, V. W.; Condra, J. H.; Hoffman, J. M.; Emini, A. E. A Nonnucleoside Reverse Transcriptase Inhibitor Active on Human Immunodeficiency Virus Type 1 Isolates Resistant to Related Inhibitors. Antimicrob. Agents Chemother. 1993, 37, 947-949.
38. Saari, W.; Hoffman, J. M.; Wai, J. S.; Fisher, T. E.; Rooney, C. S.; Smith, A. M.; Thomas, C. M.; Goldman, M. E.; O'Brien, J. A.; Nunberg, J. H.; Quintero, J. C.; Schleif, W. A.; Emini, A. E.; Stern, A. M.; Anderson, P. S. 2-Pyridinone Derivatives: A New Class of Nonnucleoside, HIV-1-Specific Reverse Transcriptase Inhibitors. J. Med. Chem. 1991, 34, 2922-2925.
39. Hoffman, J. M.; Wai, J. S.; Thomas, C. M.; Levin, R. B.; O'Brien, J. A.; Goldman, M. E. Synthesis and Evaluation of 2-Pyridinone Derivatives as HIV-1 Specific Reverse Transcriptase Inhibitors. 1. Phthalimido alkyl and -alkylamino Analogues. J. Med. Chem. 1992, 35, 3784-3791.
40. Saari, W. S.; Wai, J. S.; Fisher, T. E.; Thomas, C. M.; Hoffman, J. M.; Rooney, C. S.; Smith, A. M.; Jones, J. H.; Bamberger, D. L.; Goldman, M. E.; O'Brien, J. A.; Nunberg, J. H.; Quintero, J. C.; Schleif, W. A.; Emini, A. E.; Anderson, P. S. Synthesis and Evaluation of 2-Pyridinone Derivatives as HIV-1-Specific Reverse Transcriptase Inhibitors. 2. Analogues of 3-Aminopyridin-2(1H)-one. J. Med. Chem. 1992, 35, 3792-3802.
41. Wai, J. S.; Williams, T. M.; Bamberger, D. L.; Fisher, T. E.; Hoffman, J. M.; Hudcosky, R. J.; MacTough, S. C.; Rooney, C. S.; Saari, W. S.; Thomas, C. M.; Goldman, M. E.; O'Brien, J. A.; Emini, E. A.; Nunberg, J. H.; Quintero, J. C.; Schleif, W. A.; Anderson, P. S. Synthesis and Evaluation of 2-Pyridinone Derivatives as Specific HIV-1 Reverse Transcriptase Inhibitors. 3. Pyridyl and Phenyl Analogues of 3-Aminopyridin-2(1H)-one. J. Med. Chem. 1993, 36, 249-255.
42. Ventura, M.; Tarrago-Litvak, L.; Dollé, V.; Nguyen, C. H.; Legraverend, M.; Fleury H. J. A.; Litvak. S. Effect of nucleoside analogues and nonnucleoside inhibitors of HIV-1 reverse transcriptase on cell-free virions. Arch. Virol. 1999, 144, 513-523.
43. Hsiou, Y.; Ding, J.; Das, K.; Clark, A. D., Jr.; Boyer, P. L.; Lewi, P.; Janssen, P. A. J.; Kleim, J.-P.; Rosner, M.; Hughes, S. H.; Arnold, E. The Lys103Asn Mutation of HIV-1 RT: A Novel Mechanism of Drug Resistance. J. Mol. Biol. 2001, 309, 437-445.
44. Hopkins, A. L.; Ren, J.; Esnouf, R. M.; Willcox, B. E.; Jones, E. Y.; Ross, C.; Miyasaka, T.; Walker, R. T.; Tanaka, H.; Stammers, D. K.; Stuart, D. I.; Complexes of HIV-1 Reverse Transcriptase with Inhibitors of the HEPT Series Reveal Conformational Changes Relevant to the Design of Potent Non-Nucleoside Inhibitors. J. Med. Chem. 1988, 39, 1589-1600.
45. Hopkins, A. L.; Ren, J.; Tanaka, H.; Baba, M.; Okamato, M.; Stuart, D. I.; Stammers, D. K. Design of MKC-442 (Emivirine) Analogues with Improved Activity Against Drug-Resistant HIV Mutants. J. Med. Chem. 1999, 42, 4500-4505.
46. Hoffman, J. M.; Smith, A. M.; Rooney, C. S.; Fisher, T. E.; Wai, J. S.; Thomas, C. M.; Bamberger, D. L.; Barnes, J. L.; Williams, T. M.; Jones, J. H.; Olson, B. D.; O'Brien, J. A.; Goldman, M. E.; Nunberg, J. H.; Quintero, J. C.; Schleif, W. A.; Emini, A. E.; Anderson, P. S. Synthesis and Evaluation of 2-Pyridinone Derivatives as HIV-1-Specific Reverse Transcriptase Inhibitors. 4. 3-[2-(Benzoxazol-2-yl)ethyl]-5-ethyl-6-methylpvridin-2(1H)-one and Analogues. J. Med. Chem. 1993, 36, 953-966.
47. Dollé, V.; Nguyen, C. H.; Bisagni, E. Studies towards 4-C-Alkylation of Pyridin-2(1H)-one derivatives. Tetrahedron 1997, 53, 12505-12524.
48. Taylor, H. M.; Jones, C. D.; Davenport, J. D.; Hirsch, K. S.; Kress, T. J.; Weaver, D. Aromatase inhibition by 5-substituted pyrimidines and dihydropyrimidines. J. Med. Chem. 1987, 30, 1359-1365.
49. Marx, T.; Breitmaier, E. Chiral porphyrins with C-connected methyl residues. Liebigs Ann. Chem. 1992, 3, 183-186.
50. Pauwels, R.; Balzarini, J.; Baba, M.; Snoek, R.; Schols, D.; Herdewijn, P.; Desmyter, J.; De Clercq, E. Rapid and automated tetrazolium-based calorimetric assay for the detection of anti)-HIV compounds. J. Virol. Methods 1988, 20, 309-321.
51. See also: Chan, J. H.; Hong, J. S.; Hunter, R. N., III; Orr, G. F.; Cowan, J. R.; Sherman, D. B.; Sparks, S. M.; Reitter, B. E.; Andrews, C. W., III; Hazen, R. J.; St Clair, M.; Boone, L. R.; Ferris, R. G.; Creech, K. L.; Roberts, G. B.; Short, S. A.; Weaver, K. Ott, R. J.; Ren, J.; Hopkins, A.; Stuart, D. I.; Stammers, D. K. 2-Amino-6-arylsulfonylbenzonitriles as Nonnucleoside Reverse Transcriptase Inhibitors of HIV-1. J. Med. Chem. 2001, 44, 1866-1882.
52. Fleming, F. F.; Wang, Q. Unsaturated Nitriles: Conjugate Additions of Carbon Nucleophiles to a Recalcitrant Class of Acceptors Chem. Rev. 2003, 103, 2019-2034.
53. Proudfoot, P. R.; Hargrave, K. D.; Kapadia, S. R.; Patel, U. R.; Grozinger, K. G.; McNeil, D. W.; Cullen, E.; Cardozo, M.; Tong, L.; Kelly, T. A.; Rose, J.; David, E.; Mauldin, S. C.; Fuchs, V. U.; Vitous, J.; Hoermann, M.; Klunder, J. M.; Raghaven, P.; Skiles, J. W.; Mui, P.; Richman, D. D.; Sullivan, J. L.; Shih, C.-K.; Grob, P. M.; Adams, J. Novel Nonnucleoside Inhibitors of Human Immunodefficiency Virus Type I (HIV-1) Reverse Transcriptase. 4. 2-Substituted Dipyridodiazepinones as Potent Inhibitors of Both Wild-Type and Cysteine-181 HIV-1 Reverse transcriptase Enzymes.
54. Kelly, T. A.; Proudfoot, J. R.; McNeil, D. W.; Patel, U. R.; David, E.; Hargrave, K. D.; Grob, P. M.; Cardozo, M.; Agarwal, A.; Adams, J. Novel Nonnucleoside Inhibitors of Human Immunodefficiency Virus Type I (HIV-1) Reverse Transcriptase. 5. 4-Substituted and 2,4-Disubstituted Analogues of Nevirapine.
55. Kelly, T. A.; McNeil, D. W.; Rose, J. M.; David, E.; Shih, C.-K; Grob, P. M. Novel Nonnucleoside Inhibitors of Human Immunodefficiency Virus Type I (HIV-1) Reverse Transcriptase. 6. 2-Indol-3-yl- and 2-Azaindol-3-yl- dipyridodiazepinones.
56. Larhed, V.; Hallberg, A. Direct synthesis of cyclic ketals of acetophenones by palladium-catalyzed arylation of hydroxyalkyl vinyl ethers. J. Org. Chem. 1997, 62, 7558-7862.
57. Hertogs, K.; de Bethune, M. P.; Miller, V; Ivens, T.; Schel, P.; Van Cauwenberge, A.; Van Den Eynde, C.; Van Gerwen, V.; Azijn, H.; Van Houtte, M.; Peeters, F.; Staszewski, S.; Conant, M.; Bloor, S.; Kemp, S.; Larder, B.; Pauwels, R. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob. Agents Chemother. 1998, 42, 269-276.